Brian Kevany - Abeona Therapeutics CTO VP
| ABEO Stock | USD 5.98 0.19 3.28% |
Insider
Brian Kevany is CTO VP of Abeona Therapeutics
| Address | 6555 Carnegie Avenue, Cleveland, OH, United States, 44103 |
| Phone | 646 813 4701 |
| Web | https://www.abeonatherapeutics.com |
Abeona Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3781) % which means that it has lost $0.3781 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2738) %, meaning that it created substantial loss on money invested by shareholders. Abeona Therapeutics' management efficiency ratios could be used to measure how well Abeona Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 23rd of November 2024, Return On Tangible Assets is likely to drop to -0.89. In addition to that, Return On Capital Employed is likely to grow to -0.89. At this time, Abeona Therapeutics' Other Current Assets are very stable compared to the past year. As of the 23rd of November 2024, Non Currrent Assets Other is likely to grow to about 319.9 K, while Total Assets are likely to drop about 49.3 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Lorenz Muller | Milestone Pharmaceuticals | 60 | |
| Carl Langren | Lumos Pharma | 69 | |
| Lori CPA | Lumos Pharma | 40 | |
| Guy Rousseau | Milestone Pharmaceuticals | N/A | |
| BBA CPA | Lumos Pharma | 57 | |
| Robert MBA | Eliem Therapeutics | 56 | |
| James JD | Eliem Therapeutics | 58 | |
| MD BA | Lumos Pharma | 69 | |
| FACC FAHA | Milestone Pharmaceuticals | 66 | |
| Lisa Miller | Lumos Pharma | N/A | |
| MBA MD | Eliem Therapeutics | 63 | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| FACC MD | Milestone Pharmaceuticals | 60 | |
| Kimberly Sheehan | Milestone Pharmaceuticals | N/A | |
| Ronald CPA | RenovoRx | N/A | |
| Philippe MBA | Milestone Pharmaceuticals | 62 | |
| Bradley JD | Lumos Pharma | 45 | |
| James Ahlers | RenovoRx | 60 | |
| David MBA | Seres Therapeutics | 63 | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| Kristin Ainsworth | Seres Therapeutics | N/A | |
Management Performance
| Return On Equity | -1.27 | ||||
| Return On Asset | -0.38 |
Abeona Therapeutics Leadership Team
Elected by the shareholders, the Abeona Therapeutics' board of directors comprises two types of representatives: Abeona Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Abeona. The board's role is to monitor Abeona Therapeutics' management team and ensure that shareholders' interests are well served. Abeona Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Abeona Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph Vazzano, Chief Officer | ||
| Dmitriy MD, Chief Officer | ||
| Brian Kevany, CTO VP | ||
| Vishwas MBA, CEO President | ||
| Carl Denny, Senior Affairs | ||
| Alison Hardgrove, Vice Resources | ||
| Scott Santiamo, Director Communications | ||
| Joseph CPA, Chief Officer | ||
| Gregory Gin, Vice Communications | ||
| Jon Voss, VP Quality | ||
| Dr JD, Senior Counsel | ||
| Madhav MBA, Chief VP |
Abeona Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Abeona Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.27 | ||||
| Return On Asset | -0.38 | ||||
| Current Valuation | 173.36 M | ||||
| Shares Outstanding | 43.47 M | ||||
| Shares Owned By Insiders | 5.10 % | ||||
| Shares Owned By Institutions | 77.54 % | ||||
| Number Of Shares Shorted | 2.64 M | ||||
| Price To Earning | 0.11 X | ||||
| Price To Book | 5.68 X | ||||
| Price To Sales | 61.63 X |
Pair Trading with Abeona Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Abeona Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Abeona Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Abeona Stock
| 0.58 | BACK | IMAC Holdings | PairCorr |
| 0.57 | NKTX | Nkarta Inc | PairCorr |
| 0.55 | CYRX | Cryoport | PairCorr |
| 0.55 | KEP | Korea Electric Power | PairCorr |
| 0.54 | VALN | Valneva SE ADR | PairCorr |
The ability to find closely correlated positions to Abeona Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Abeona Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Abeona Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Abeona Therapeutics to buy it.
The correlation of Abeona Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Abeona Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Abeona Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Abeona Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abeona Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Abeona Stock, please use our How to Invest in Abeona Therapeutics guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abeona Therapeutics. If investors know Abeona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abeona Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.05) | Quarterly Revenue Growth (1.00) | Return On Assets (0.38) | Return On Equity (1.27) |
The market value of Abeona Therapeutics is measured differently than its book value, which is the value of Abeona that is recorded on the company's balance sheet. Investors also form their own opinion of Abeona Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Abeona Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abeona Therapeutics' market value can be influenced by many factors that don't directly affect Abeona Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abeona Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abeona Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abeona Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.